SEC Filing Analysis: Amphastar Pharmaceuticals, Inc. (AMPH)

Executive Summary

• Trading Significance: Low
• Key Takeaway: A director executed a minor, pre-planned sale of common stock, representing a negligible portion of their holdings and the company's market value.
• Market Impact: Negligible, due to the transaction's small size and its execution under a Rule 10b5-1 plan.

Company Information

Field	Value
Company	Amphastar Pharmaceuticals, Inc.
Ticker Symbol	AMPH
CIK	0001297184
Industry	PHARMACEUTICAL PREPARATIONS [2834]

Insider Information

Field	Value
Name	Petersen Floyd F.
CIK	0001611286
Title/Position	null
Relationship	Director

Transaction Details

Field	Value
Form Type	4
Transaction Date	2025-11-03
Transaction Code	S (Sale)
Security Type	Common Stock
Shares Involved	500
Price Per Share	$25.2662
Total Value	$12,633.10
Shares Owned After	75,531
Ownership Type	Direct

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$12,633.10
% of Market Cap	0.0011%
Shares Transacted	500
% of Shares Outstanding	0.0011%
Post-Transaction Ownership	75,531 shares (0.16% of outstanding)
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: The $12.6k sale is immaterial against Amphastar's $1.19 billion market capitalization.
• Ownership Concentration: The sale represents a very small fraction (approx. 0.66%) of the director's total holdings, indicating a minor portfolio adjustment rather than a significant change in position.
• Transaction Significance: The transaction is well below the 0.1% threshold for both market cap and shares outstanding, confirming its low significance.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: The transaction is too small to influence the market. Its execution under a pre-scheduled 10b5-1 plan removes any implication that it was based on new non-public information.

Volume & Sentiment

• Expected Volume Impact: No discernible impact on trading volume is expected.
• Sentiment Indicator: Neutral. The filing is routine and unlikely to influence investor sentiment.

Additional Context

Special Circumstances

• The filing notes that the sale was made pursuant to a Rule 10b5-1 trading plan adopted on November 26, 2024. This indicates the sale was pre-planned and not a reaction to recent market or company events.